c-Raf in KRas Mutant Cancers: A Moving Target

Publication date: 12 February 2018
Source:Cancer Cell, Volume 33, Issue 2
Author(s): Frank McCormick
Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRas^G12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.

Teaser

Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRas^G12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.


from Cancer via ola Kala on Inoreader http://ift.tt/2G7IvY0
via IFTTT